Biopulse srl, Naples, Italy.
University Campus Biomedico, Rome, Italy.
Open Vet J. 2020 Oct;10(3):267-271. doi: 10.4314/ovj.v10i3.4. Epub 2020 Jul 31.
fFeline injection-site sarcomas (FISSs) are mesenchymal tumors that can occur in cats after injections of different medical agents and are easily prone to recurrence.
The aims of this study were to report treatment outcomes for cats with feline injection-site sarcomas (FISSs) treated with both bleomycin and cisplatin, per adjuvant electrochemotherapy (ECT) protocol.
The medical records of cats with a diagnosis of FISS that were treated with ECT using both bleomycin and cisplatin were retrospectively evaluated. A total of 27 cats were available for statistical evaluation of their response. The cats received intravenous 20 mg/m2 bleomycin, and the tumor bed and margins were infiltrated with cisplatin at the dose of 0.5 mg/cm2. Then, the trains of permeabilizing biphasic electric pulses lasting 50 + 50 µseconds each were delivered in bursts of 1,300 V/cm using caliper electrodes under sedation. A second session was performed 2 weeks later.
Side effects were limited to local inflammation in three cats. Three cats developed local tumor recurrence at days 180, 180, and 545 after surgery, two cats developed recurrence and metastases at 100 and 505 days after surgery, and two cats experienced distant metastases. A median time to recurrence could not be calculated as over 80% of the study population remained disease free or were censored due to death from other causes. Mean survival time was 985 days, and median cumulative survival for all cases was 1,000 days.
When compared to historical controls, the results of this study demonstrate the superior rates of tumor-free survival and disease-free interval. This adjuvant therapy could be a useful addition to the current options for FISS in consideration of its efficacy, limited toxicity, and ease of administration.
猫注射部位肉瘤（FISSs）是一种间叶组织肿瘤，可在猫接受不同药物注射后发生，且容易复发。
本研究旨在报告使用博来霉素和顺铂辅助电化学治疗（ECT）方案治疗猫注射部位肉瘤（FISSs）的治疗结果。
回顾性评估了诊断为 FISS 并接受 ECT 联合博来霉素和顺铂治疗的猫的病历。共有 27 只猫可用于统计评估其反应。猫接受静脉内 20mg/m2 的博来霉素，肿瘤床和边缘用 0.5mg/cm2 的顺铂浸润。然后，在镇静下使用卡尺电极以 1,300V/cm 的幅度传递持续 50+50µs 的双相渗透脉冲串。两周后进行第二次治疗。
仅 3 只猫出现了局限于局部炎症的副作用。3 只猫在手术后 180、180 和 545 天发生局部肿瘤复发，2 只猫在手术后 100 和 505 天发生复发和转移，2 只猫发生远处转移。无法计算复发的中位时间，因为超过 80%的研究人群仍处于无疾病状态或因其他原因死亡而被删失。平均生存时间为 985 天，所有病例的中位累积生存率为 1,000 天。
与历史对照相比，本研究结果表明无肿瘤生存率和无病间隔率更高。考虑到其疗效、有限的毒性和给药的便利性，这种辅助治疗可能是 FISS 目前治疗方案的有益补充。
